General Archives - Gilde Healthcare

Menu
Menu
Home

latest
news

Gilde Healthcare portfolio company Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04 at ACR Convergence 2024

Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is presenting the results from its positive Phase II trial of LEVI-04 at the American College of Rheumatology's annual meeting, ACR Convergence 2024, being held from 14 November to 19 November, 2024 in Washington, DC. Headline results were first announced in August 2024. LEVI-04...
November 14, 2024

Gilde Healthcare company Noema Pharma Announces First Patients Dosed in Phase 2b Study for Tourette Syndrome

test Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global Phase 2b study evaluating the safety and efficacy of gemlapodect (NOE-105) in Tourette syndrome. NOE-TTS-201 (NCT06315751) is a Phase 2b, […]

Gilde Healthcare invests in SynOx Therapeutics and company doses first patients in Phase 3 trial

test Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted Antibody, for the Treatment of Tenosynovial Giant Cell Tumour TANGENT Study Underway with First Patients Dosed SynOx Therapeutics Limited (“SynOx”), a late clinical-stage biopharmaceutical company developing a […]

Gilde Healthcare company Lumicks secures €20 Million from European investment bank to accelerate drug discovery

Amsterdam-based LUMICKS signs €20 million venture debt with EIB to accelerate the development and launch of its new product, designed to advance immunotherapy development for cancer research. LUMICKS’ next generation high-throughput cell avidity platform aims to transform the drug discovery process by replacing traditional screening methods, expediting...

Gilde Healthcare co-leads in an oversubscribed £80 million Series B financing in Purespring Therapeutics

Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy (IgAN) Round brings in new biotech investors, Gilde Healthcare, Sofinnova Partners, Forbion, and British Patient Capital with founding investor Syncona Purespring Therapeutics,...

Gilde Healthcare company Adcendo announces IND clearance by FDA for the phase I/II study of ADCE-D01

ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor which is highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma (STS) subtypes The Phase I/II ADCElerate-01 trial is designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ADCE-D01 as a monotherapy in...

GILDE HEALTHCARE COMPANY SYNEXA LIFE SCIENCES ACQUIRES ALDERLEY ANALYTICAL TO EXPAND BIOANALYSIS CAPABILITIES IN DRUG DEVELOPMENT

Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, announces the acquisition of Alderley Analytical Ltd, based in Manchester, UK. The transaction marks an important milestone in Synexa’s ‘buy and build’ growth strategy, underpinning the company’s vision to be ‘the scientific partner of choice for biomarker...

Gilde Healthcare company Tagworks Pharmaceuticals Appoints Ken Mills as Chief Executive Officer

Biotech industry veteran to lead Tagworks as the company prepares to bring its novel platform and lead antibody-drug (ADC) conjugate program for solid tumors into the clinic in 2025 Founding CEO Marc Robillard, Ph.D., will continue in role of Chief Scientific Officer and as a member of...

Gilde Healthcare company Spire Health merges with Wellinks to form Industry Leader in Predictive Patient Care for Cardiopulmonary Health

Wellinks, the industry leader in virtual-led cardiopulmonary care, announced today it has merged with Spire Health in a non-cash transaction. The transaction merges Spire’s novel patient monitoring technology with Wellinks highly specialized virtual-led cardiopulmonary care model creating a first of its kind fully integrated Predictive Patient Care company....
Loading...
These were all messages
6c2a5b5093